Inventor
PASTAN IRA
US56 patents
⚠️ This page may combine multiple inventors who share the name “PASTAN IRA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
US HEALTH
41 patentsUS7081518B1Jul 25, 2006
Anti-mesothelin antibodies having high binding affinity
US HEALTH109 citations98
US6083502AJul 4, 2000
Mesothelium antigen and methods and kits for targeting it
US HEALTH98 citations98
US5614191AMar 25, 1997
IL-13 receptor specific chimeric proteins and uses thereof
US HEALTH118 citations98
US5512658AApr 30, 1996
Pseudomonas exotoxins (PE) and conjugates thereof having lower animal toxicity with high cytocidal activity through substitution of positively charged amino acids
US HEALTH149 citations98
US4545985AOct 8, 1985
Pseudomonas exotoxin conjugate immunotoxins
US HEALTH160 citations98
US6518061B1Feb 11, 2003
IL-13 receptor specific chimeric proteins and uses thereof
US HEALTH78 citations97
US6011002AJan 4, 2000
Circularly permuted ligands and circularly permuted chimeric molecules
US HEALTH116 citations97
US5608039AMar 4, 1997
Single chain B3 antibody fusion proteins and their uses
US HEALTH163 citations97
US6153430ANov 28, 2000
Nucleic acid encoding mesothelin, a differentiation antigen present on mesothelium, mesotheliomas and ovarian cancers
US HEALTH81 citations96
US6074644AJun 13, 2000
Nucleic acids encoding immunotoxins containing a disulfide-stabilized antibody fragment replacing half or more of domain IB of pseudomonas exotoxin, and methods of use of the encoded immunotoxins
US HEALTH59 citations96
US5980895ANov 9, 1999
Immunotoxin containing a disulfide-stabilized antibody fragment joined to a Pseudomonas exotoxin that does not require proteolytic activation
US HEALTH45 citations96
US5705163AJan 6, 1998
Target-specific, cytotoxic, recombinant pseudomonas exotoxin
US HEALTH49 citations96
US5458878AOct 17, 1995
P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
US HEALTH60 citations96
US5320956AJun 14, 1994
Monoclonal antibody useful for the diagnosis of cancer
US HEALTH56 citations96
US7541034B1Jun 2, 2009
Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors
US HEALTH93 citations95
US5919456AJul 6, 1999
IL-13 receptor specific chimeric proteins
US HEALTH70 citations95
US5889157AMar 30, 1999
Humanized B3 antibody fragments, fusion proteins, and uses thereof
US HEALTH64 citations95
US5242813ASep 7, 1993
Mouse monoclonal antibodies specific for normal primate tissue, malignant human cultural cell lines human tumors
US HEALTH51 citations95
US5759782AJun 2, 1998
Cellular apoptosis susceptibility protein (CSP) and antisense CSP
US HEALTH21 citations93
US7375183B1May 20, 2008
Mesothelin, immunogenic peptides derived therefrom, and compositions comprising mesothelin, or immunogenic peptides thereof
US HEALTH23 citations92
US7129332B2Oct 31, 2006
Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
US HEALTH29 citations92
US6426075B1Jul 30, 2002
Protease-activatable pseudomonas exotoxin A-like proproteins
US HEALTH33 citations92
US6423513B1Jul 23, 2002
Polynucleotides encoding protease-activatable pseudomonas exotoxin a-like proproteins
US HEALTH30 citations92
US5981726ANov 9, 1999
Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof
US HEALTH40 citations92
US5846535ADec 8, 1998
Methods for reducing tumor cell growth by using antibodies with broad tumor reactivity and limited normal tissue reactivity
US HEALTH27 citations92
US5817313AOct 6, 1998
Monoclonal antibodies and conjugates thereof useful for the treatment of cancer
US HEALTH26 citations92
US5705156AJan 6, 1998
Psuedomonas exotoxins of low animal toxicity and high cytocidal activity
US HEALTH24 citations92
US5525337AJun 11, 1996
Monoclonal antibody binding cell surface antigens for diagnosing cancer
US HEALTH35 citations92
US7777019B2Aug 17, 2010
Mutated Anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells
US HEALTH16 citations91
US6099842AAug 8, 2000
Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US HEALTH72 citations91
US5990296ANov 23, 1999
Single chain B3 antibody fusion proteins and their uses
US HEALTH37 citations91
US5166059ANov 24, 1992
Gene therapy using gene fusions for genetic or acquired disorders
US HEALTH51 citations91
US7999077B2Aug 16, 2011
IRTA2 antibodies and methods of use
US HEALTH23 citations88
US5849998ADec 15, 1998
Transgenic animals expressing a multidrug resistance cDNA
US HEALTH21 citations87
US5928637AJul 27, 1999
Methods of inducing multidrug resistance using human MDR1 cDNA
US HEALTH17 citations83
US6232086B1May 15, 2001
Method for detecting cancer cells
US HEALTH13 citations82
US6156564ADec 5, 2000
Cellular apoptosis susceptibility protein (CSP) and antisense CSP
US HEALTH6 citations74
US6072031AJun 6, 2000
Cellular apoptosis susceptibility protein (CSP)
US HEALTH8 citations74
US6287562B1Sep 11, 2001
Methods of inhibiting the growth of cells bearing LewisY antigens using B1, B3, or B5 targeted immunoconjugates
US HEALTH9 citations73
US5851819ADec 22, 1998
Vectors carrying MDR1 cDNA which confer multidrug resistance on transduced cells
US HEALTH11 citations72
US7052703B1May 30, 2006
T-cell receptorγ alternate reading frame protein, (TARP) and uses thereof
US HEALTH9 citations71
US COMMERCE
3 patentsHO MITCHELL
2 patentsPASTAN IRA
1 patentFITZGERALD DAVID J
1 patentUS DEPARTMENT OF HEALTH & HUMA
1 patentUS GOV HEALTH & HUMAN SERV
1 patentShowing the top 50 of 56 patents by PatentIndex Score.